References

1. Weiss, A.K.H.; Loeffler, J.R.; Liedl, K.R.; Gstach, H.; Jansen-Dürr, P. The fumarylacetoacetate hydrolase (FAH) superfamily of enzymes: Multifunctional enzymes from microbes to mitochondria. Biochem. Soc. Trans. 2018, 46, 295–309. [Google Scholar] [CrossRef]
2. Flydal, M.I.; Martinez, A. Phenylalanine hydroxylase: Function, structure, and regulation. IUBMB Life 2013, 65, 341–349. [Google Scholar] [CrossRef]
3. Williams, R.A.; Mamotte, C.D.; Burnett, J.R. Phenylketonuria: An inborn error of phenylalanine metabolism. Clin. Biochem. Rev. 2008, 29, 31–41. [Google Scholar] [PubMed]
4. Arturo, E.C.; Gupta, K.; Héroux, A.; Stith, L.; Cross, P.J.; Parker, E.J.; Loll, P.J.; Jaffe, E.K. First structure of full-length mammalian phenylalanine hydroxylase reveals the architecture of an autoinhibited tetramer. Proc. Natl. Acad. Sci. USA 2016, 113, 2394–2399. [Google Scholar] [CrossRef]
5. Arturo, E.C.; Gupta, K.; Hansen, M.R.; Borne, E.; Jaffe, E.K. Biophysical characterization of full-length human phenylalanine hydroxylase provides a deeper understanding of its quaternary structure equilibrium. J. Biol. Chem. 2019, 294, 10131–10145. [Google Scholar] [CrossRef] [PubMed]
6. Timm, D.E.; Mueller, H.A.; Bhanumoorthy, P.; Harp, J.M.; Bunick, G.J. Crystal structure and mechanism of a carbon-carbon bond hydrolase. Structure 1999, 7, 1023–1033. [Google Scholar] [CrossRef]
7. Macias, I.; Laín, A.; Bernardo-Seisdedos, G.; Gil, D.; Gonzalez, E.; Falcon-Perez, J.M.; Millet, O. Hereditary tyrosinemia type I-associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate. J. Biol. Chem. 2019, 294, 13051–13060. [Google Scholar] [CrossRef]
8. Angileri, F.; Bergeron, A.; Morrow, G.; Lettre, F.; Gray, G.; Hutchin, T.; Ball, S.; Tanguay, R.M. Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1. JIMD Rep. 2015, 19, 43–58. [Google Scholar] [CrossRef]
9. Scriver, C.R. The PAH gene, phenylketonuria, and a paradigm shift. Hum. Mutat. 2007, 28, 831–845. [Google Scholar] [CrossRef]
10. Medes, G. A new error of tyrosine metabolism: Tyrosinosis. The intermediary metabolism of tyrosine and phenylalanine. Biochem. J. 1932, 26, 917–940. [Google Scholar] [CrossRef]
11. Lindblad, B.; Lindstedt, S.; Steen, G. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA 1977, 74, 4641–4645. [Google Scholar] [CrossRef]
12. Fällström, S.-P.; Lindblad, B.; Lindstedt, S.; Steen, G. Hereditary tyrosinemia-fumarylacetoacetase deficiency. Pediatric Res. 1979, 13, 78. [Google Scholar] [CrossRef]
13. Berger, R.; Smit, G.P.; Stoker-de Vries, S.A.; Duran, M.; Ketting, D.; Wadman, S.K. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia. Clin. Chim. Acta 1981, 114, 37–44. [Google Scholar] [CrossRef]
14. Kvittingen, E.; Jellum, E.; Stokke, O. Assay of fumarylacetoacetate fumarylhydrolase in human liver—Deficient activity in a case of hereditary tyrosinemia. Clin. Chim. Acta 1981, 115, 311–319. [Google Scholar] [CrossRef]
15. Cassiman, D.; Zeevaert, R.; Holme, E.; Kvittingen, E.A.; Jaeken, J. A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): A case report. Orphanet J. Rare Dis. 2009, 4, 28. [Google Scholar] [CrossRef] [PubMed]
16. Garbade, S.F.; Shen, N.; Himmelreich, N.; Haas, D.; Trefz, F.K.; Hoffmann, G.F.; Burgard, P.; Blau, N. Allelic phenotype values: A model for genotype-based phenotype prediction in phenylketonuria. Genet. Med. 2019, 21, 580–590. [Google Scholar] [CrossRef]
17. Richards, D.Y.; Winn, S.R.; Dudley, S.; Nygaard, S.; Mighell, T.L.; Grompe, M.; Harding, C.O. AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria. Mol. Ther. Methods Clin. Dev. 2020, 17, 234–245. [Google Scholar] [CrossRef]
18. van Spronsen, F.J.; van Rijn, M.; Bekhof, J.; Koch, R.; Smit, P.G. Phenylketonuria: Tyrosine supplementation in phenylalanine-restricted diets. Am. J. Clin. Nutr. 2001, 73, 153–157. [Google Scholar] [CrossRef]
19. Pecimonova, M.; Kluckova, D.; Csicsay, F.; Reblova, K.; Krahulec, J.; Procházkova, D.; Skultety, L.; Kadasi, L.; Soltysova, A. Structural and Functional Impact of Seven Missense Variants of Phenylalanine Hydroxylase. Genes 2019, 10, 459. [Google Scholar] [CrossRef]
20. Flydal, M.I.; Alcorlo-Pagés, M.; Johannessen, F.G.; Martínez-Caballero, S.; Skjærven, L.; Fernandez-Leiro, R.; Martinez, A.; Hermoso, J.A. Structure of full-length human phenylalanine hydroxylase in complex with tetrahydrobiopterin. Proc. Natl. Acad. Sci. USA 2019, 116, 11229–11234. [Google Scholar] [CrossRef] [PubMed]
21. Wettstein, S.; Underhaug, J.; Perez, B.; Marsden, B.D.; Yue, W.W.; Martinez, A.; Blau, N. Linking genotypes database with locus-specific database and genotype-phenotype correlation in phenylketonuria. Eur. J. Hum. Genet. 2015, 23, 302–309. [Google Scholar] [CrossRef] [PubMed]
22. Jaffe, E.K. New protein structures provide an updated understanding of phenylketonuria. Mol. Genet. Metab. 2017, 121, 289–296. [Google Scholar] [CrossRef] [PubMed]
23. Patel, D.; Kopec, J.; Fitzpatrick, F.; McCorvie, T.J.; Yue, W.W. Structural basis for ligand-dependent dimerization of phenylalanine hydroxylase regulatory domain. Sci. Rep. 2016, 6, 23748. [Google Scholar] [CrossRef] [PubMed]
24. Sarkissian, C.N.; Ying, M.; Scherer, T.; Thöny, B.; Martinez, A. The mechanism of BH4 -responsive hyperphenylalaninemia—As it occurs in the ENU1/2 genetic mouse model. Hum. Mutat. 2012, 33, 1464–1473. [Google Scholar] [CrossRef] [PubMed]
25. Jung-Kc, K.; Himmelreich, N.; Prestegård, K.S.; Shi, T.S.; Scherer, T.; Ying, M.; Jorge-Finnigan, A.; Thöny, B.; Blau, N.; Martinez, A. Phenylalanine hydroxylase variants interact with the co-chaperone DNAJC12. Hum. Mutat. 2019, 40, 483–494. [Google Scholar] [CrossRef] [PubMed]
26. Eichinger, A.; Danecka, M.K.; Möglich, T.; Borsch, J.; Woidy, M.; Büttner, L.; Muntau, A.C.; Gersting, S.W. Secondary BH4 deficiency links protein homeostasis to regulation of phenylalanine metabolism. Hum. Mol. Genet. 2018, 27, 1732–1742. [Google Scholar] [CrossRef]
27. Waters, P.J. Degradation of mutant proteins, underlying “loss of function” phenotypes, plays a major role in genetic disease. Curr. Issues Mol. Biol. 2001, 3, 57–65. [Google Scholar]
28. Wang, J.; Maldonado, M.A. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol. Immunol. 2006, 3, 255–261. [Google Scholar] [PubMed]
29. Døskeland, A.P.; Flatmark, T. Conjugation of phenylalanine hydroxylase with polyubiquitin chains catalysed by rat liver enzymes. Biochim. Biophys. Acta 2001, 1547, 379–386. [Google Scholar] [CrossRef]
30. Blau, N.; Martinez, A.; Hoffmann, G.F.; Thöny, B. DNAJC12 deficiency: A new strategy in the diagnosis of hyperphenylalaninemias. Mol. Genet. Metab. 2018, 123, 1–5. [Google Scholar] [CrossRef] [PubMed]
31. Scheller, R.; Stein, A.; Nielsen, S.V.; Marin, F.I.; Gerdes, A.M.; Di Marco, M.; Papaleo, E.; Lindorff-Larsen, K.; Hartmann-Petersen, R. Toward mechanistic models for genotype-phenotype correlations in phenylketonuria using protein stability calculations. Hum. Mutat. 2019, 40, 444–457. [Google Scholar] [CrossRef] [PubMed]
32. Gersting, S.W.; Kemter, K.F.; Staudigl, M.; Messing, D.D.; Danecka, M.K.; Lagler, F.B.; Sommerhoff, C.P.; Roscher, A.A.; Muntau, A.C. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am. J. Hum. Genet. 2008, 83, 5–17. [Google Scholar] [CrossRef]
33. Bergeron, A.; D’Astous, M.; Timm, D.E.; Tanguay, R.M. Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1. J. Biol. Chem. 2001, 276, 15225–15231. [Google Scholar] [CrossRef] [PubMed]
34. Stone, W.L.; Basit, H.; Los, E. Phenylketonuria. In StatPearls [Internet]; StatPearls Publishing: St. Petersburg, FL, USA, 2019. [Google Scholar]
35. Shi, Z.; Sellers, J.; Moult, J. Protein stability and in vivo concentration of missense mutations in phenylalanine hydroxylase. Proteins 2012, 80, 61–70. [Google Scholar] [CrossRef]
36. Sandhu, I.S.; Maksim, N.J.; Amouzougan, E.A.; Gallion, B.W.; Raviele, A.L.; Ooi, A. Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1). Biochem. Soc. Trans. 2015, 43, 650–656. [Google Scholar] [CrossRef] [PubMed]
37. Regier, D.S.; Greene, C.L. Phenylalanine Hydroxylase Deficiency; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., Amemiya, A., Eds.; GeneReviews®; University of Washington: Seattle, WA, USA, 1993. [Google Scholar]
38. Underhaug, J.; Aubi, O.; Martinez, A. Phenylalanine hydroxylase misfolding and pharmacological chaperones. Curr. Top. Med. Chem. 2012, 12, 2534–2545. [Google Scholar] [CrossRef]
39. Muntau, A.C.; du Moulin, M.; Feillet, F. Diagnostic and therapeutic recommendations for the treatment of hyperphenylalaninemia in patients 0–4 years of age. Orphanet J. Rare Dis. 2018, 13, 173. [Google Scholar] [CrossRef]
40. Sheth, J.J.; Ankleshwaria, C.M.; Pawar, R.; Sheth, F.J. Identification of Novel Mutations in FAH Gene and Prenatal Diagnosis of Tyrosinemia in Indian Family. Case Rep. Genet. 2012, 2012, 428075. [Google Scholar] [CrossRef]
41. Loeber, J.G. Neonatal screening in Europe; the situation in 2004. J. Inherit. Metab. Dis. 2007, 30, 430–438. [Google Scholar] [CrossRef]
42. Gundorova, P.; Stepanova, A.A.; Kuznetsova, I.A.; Kutsev, S.I.; Polyakov, A.V. Genotypes of 2579 patients with phenylketonuria reveal a high rate of BH4 non-responders in Russia. PLoS ONE 2019, 14, e0211048. [Google Scholar] [CrossRef]
43. Zhang, X.; Chen, H.X.; Li, C.; Zhang, G.; Liao, S.Y.; Peng, Z.C.; Lai, X.P.; Wang, L.L. Rapid detection of PAH gene mutations in Chinese people. BMC Med. Genet. 2019, 20, 135. [Google Scholar] [CrossRef] [PubMed]
44. Biglari, A.; Saffari, F.; Rashvand, Z.; Alizadeh, S.; Najafipour, R.; Sahmani, M. Mutations of the phenylalanine hydroxylase gene in Iranian patients with phenylketonuria. Springerplus 2015, 4, 542. [Google Scholar] [CrossRef] [PubMed]
45. Dursun, A.; Ozgül, R.K.; Sivri, S.; Tokatlı, A.; Güzel, A.; Mesci, L.; Kılıç, M.; Aliefendioglu, D.; Ozçay, F.; Gündüz, M.; et al. Mutation spectrum of fumarylacetoacetase gene and clinical aspects of tyrosinemia type I disease. JIMD Rep. 2011, 1, 17–21. [Google Scholar] [CrossRef] [PubMed]
46. Yasir Zahoor, M.; Cheema, H.A.; Ijaz, S.; Fayyaz, Z. Genetic Analysis of Tyrosinemia Type 1 and Fructose-1, 6 Bisphosphatase Deficiency Affected Pakistani Cohorts. Fetal Pediatr. Pathol. 2019, 1–11. [Google Scholar] [CrossRef]
47. Pilla, E.; Schneider, K.; Bertolotti, A. Coping with Protein Quality Control Failure. Annu. Rev. Cell Dev. Biol. 2017, 33, 439–465. [Google Scholar] [CrossRef]
48. Wolff, S.; Weissman, J.S.; Dillin, A. Differential scales of protein quality control. Cell 2014, 157, 52–64. [Google Scholar] [CrossRef]
49. Zhou, H.X. Influence of crowded cellular environments on protein folding, binding, and oligomerization: Biological consequences and potentials of atomistic modeling. FEBS Lett. 2013, 587, 1053–1061. [Google Scholar] [CrossRef]
50. Ashaq, I.; Shajrul, A.; Akbar, M.; Rashid, F. Protein misfolding diseases: In perspective of gain and loss of function. In Proteostasis and Chaperone Surveillance; Springer: Berlin, Germany, 2015; pp. 105–118. [Google Scholar]
51. Lodish, H.; Berk, A.; Zipursky, S.L.; Matsudaira, P.; Baltimore, D.; Darnell, J. Hierarchical structure of proteins. In Molecular Cell Biology, 4th ed.; WH Freeman: New York, NY, USA, 2000. [Google Scholar]
52. Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. The shape and structure of proteins. In Molecular Biology of the Cell, 4th ed.; Garland Science: New York, NY, USA, 2002. [Google Scholar]
53. Hartl, F.U.; Hayer-Hartl, M. Converging concepts of protein folding in vitro and in vivo. Nat. Struct. Mol. Biol. 2009, 16, 574–581. [Google Scholar] [CrossRef]
54. Chen, B.; Retzlaff, M.; Roos, T.; Frydman, J. Cellular strategies of protein quality control. Cold Spring Harb. Perspect. Biol. 2011, 3, a004374. [Google Scholar] [CrossRef] [PubMed]
55. Hartl, F.U. Protein Misfolding Diseases. Annu. Rev. Biochem. 2017, 86, 21–26. [Google Scholar] [CrossRef]
56. Sahni, N.; Yi, S.; Taipale, M.; Fuxman Bass, J.I.; Coulombe-Huntington, J.; Yang, F.; Peng, J.; Weile, J.; Karras, G.I.; Wang, Y.; et al. Widespread macromolecular interaction perturbations in human genetic disorders. Cell 2015, 161, 647–660. [Google Scholar] [CrossRef] [PubMed]
57. Fredrickson, E.K.; Gardner, R.G. Selective destruction of abnormal proteins by ubiquitin-mediated protein quality control degradation. Semin. Cell Dev. Biol. 2012, 23, 530–537. [Google Scholar] [CrossRef]
58. Tyedmers, J.; Mogk, A.; Bukau, B. Cellular strategies for controlling protein aggregation. Nat. Rev. Mol. Cell Biol. 2010, 11, 777–788. [Google Scholar] [CrossRef]
59. Duncan, E.J.; Cheetham, M.E.; Chapple, J.P.; van der Spuy, J. The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease. Subcell. Biochem. 2015, 78, 243–273. [Google Scholar] [CrossRef]
60. Finka, A.; Sharma, S.K.; Goloubinoff, P. Multi-layered molecular mechanisms of polypeptide holding, unfolding and disaggregation by HSP70/HSP110 chaperones. Front. Mol. Biosci. 2015, 2, 29. [Google Scholar] [CrossRef] [PubMed]
61. Jørgensen, M.M.; Jensen, O.N.; Holst, H.U.; Hansen, J.J.; Corydon, T.J.; Bross, P.; Bolund, L.; Gregersen, N. Grp78 is involved in retention of mutant low density lipoprotein receptor protein in the endoplasmic reticulum. J. Biol. Chem. 2000, 275, 33861–33868. [Google Scholar] [CrossRef] [PubMed]
62. Gámez, A.; Pérez, B.; Ugarte, M.; Desviat, L.R. Expression analysis of phenylketonuria mutations. Effect on folding and stability of the phenylalanine hydroxylase protein. J. Biol. Chem. 2000, 275, 29737–29742. [Google Scholar] [CrossRef]
63. Bross, P.; Andresen, B.S.; Gregersen, N. Impaired folding and subunit assembly as disease mechanism: The example of medium-chain acyl-CoA dehydrogenase deficiency. Prog. Nucleic Acid Res. Mol. Biol. 1998, 58, 301–337. [Google Scholar] [CrossRef]
64. Hartl, F.U.; Bracher, A.; Hayer-Hartl, M. Molecular chaperones in protein folding and proteostasis. Nature 2011, 475, 324–332. [Google Scholar] [CrossRef]
65. Hartl, F.U.; Hayer-Hartl, M. Molecular chaperones in the cytosol: From nascent chain to folded protein. Science 2002, 295, 1852–1858. [Google Scholar] [CrossRef]
66. Kriegenburg, F.; Jakopec, V.; Poulsen, E.G.; Nielsen, S.V.; Roguev, A.; Krogan, N.; Gordon, C.; Fleig, U.; Hartmann-Petersen, R. A chaperone-assisted degradation pathway targets kinetochore proteins to ensure genome stability. PLoS Genet. 2014, 10, e1004140. [Google Scholar] [CrossRef] [PubMed]
67. Demand, J.; Alberti, S.; Patterson, C.; Höhfeld, J. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr. Biol. 2001, 11, 1569–1577. [Google Scholar] [CrossRef]
68. Ciechanover, A.; Kwon, Y.T. Protein Quality Control by Molecular Chaperones in Neurodegeneration. Front. Neurosci. 2017, 11, 185. [Google Scholar] [CrossRef]
69. Radons, J. The human HSP70 family of chaperones: Where do we stand? Cell Stress Chaperones 2016, 21, 379–404. [Google Scholar] [CrossRef]
70. Li, J.; Soroka, J.; Buchner, J. The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones. Biochim. Biophys. Acta 2012, 1823, 624–635. [Google Scholar] [CrossRef] [PubMed]
71. Karagöz, G.E.; Rüdiger, S.G. Hsp90 interaction with clients. Trends Biochem. Sci. 2015, 40, 117–125. [Google Scholar] [CrossRef]
72. Taipale, M.; Jarosz, D.F.; Lindquist, S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat. Rev. Mol. Cell. Biol. 2010, 11, 515–528. [Google Scholar] [CrossRef] [PubMed]
73. Röhl, A.; Rohrberg, J.; Buchner, J. The chaperone Hsp90: Changing partners for demanding clients. Trends Biochem. Sci. 2013, 38, 253–262. [Google Scholar] [CrossRef] [PubMed]
74. Pearl, L.H.; Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75, 271–294. [Google Scholar] [CrossRef]
75. Horwich, A.L.; Fenton, W.A. Chaperonin-assisted protein folding: A chronologue. Q. Rev. Biophys. 2020, 53, e4. [Google Scholar] [CrossRef]
76. Dun, M.D.; Aitken, R.J.; Nixon, B. The role of molecular chaperones in spermatogenesis and the post-testicular maturation of mammalian spermatozoa. Hum. Reprod. Update 2012, 18, 420–435. [Google Scholar] [CrossRef] [PubMed]
77. Cyr, D.M.; Ramos, C.H. Specification of Hsp70 function by Type I and Type II Hsp40. Subcell. Biochem. 2015, 78, 91–102. [Google Scholar] [CrossRef]
78. Yim, W.W.; Mizushima, N. Lysosome biology in autophagy. Cell Discov. 2020, 6, 6. [Google Scholar] [CrossRef] [PubMed]
79. Sarodaya, N.; Karapurkar, J.; Kim, K.S.; Hong, S.H.; Ramakrishna, S. The Role of Deubiquitinating Enzymes in Hematopoiesis and Hematological Malignancies. Cancers 2020, 12, 1103. [Google Scholar] [CrossRef] [PubMed]
80. Haq, S.; Ramakrishna, S. Deubiquitylation of deubiquitylases. Open Biol. 2017, 7, 170016. [Google Scholar] [CrossRef] [PubMed]
81. Zheng, Q.; Huang, T.; Zhang, L.; Zhou, Y.; Luo, H.; Xu, H.; Wang, X. Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases. Front. Aging Neurosci. 2016, 8, 303. [Google Scholar] [CrossRef]
82. Díaz-Villanueva, J.F.; Díaz-Molina, R.; García-González, V. Protein Folding and Mechanisms of Proteostasis. Int. J. Mol. Sci. 2015, 16, 17193–17230. [Google Scholar] [CrossRef]
83. Campanella, C.; Pace, A.; Caruso Bavisotto, C.; Marzullo, P.; Marino Gammazza, A.; Buscemi, S.; Palumbo Piccionello, A. Heat Shock Proteins in Alzheimer’s Disease: Role and Targeting. Int. J. Mol. Sci. 2018, 19, 2603. [Google Scholar] [CrossRef]
84. Das, S.; Ramakrishna, S.; Kim, K.S. Critical Roles of Deubiquitinating Enzymes in the Nervous System and Neurodegenerative Disorders. Mol. Cells 2020, 43, 203–214. [Google Scholar] [CrossRef]
85. Poondla, N.; Chandrasekaran, A.P.; Kim, K.S.; Ramakrishna, S. Deubiquitinating enzymes as cancer biomarkers: New therapeutic opportunities? BMB Rep. 2019, 52, 181–189. [Google Scholar] [CrossRef]
86. Nanduri, B.; Suvarnapunya, A.E.; Venkatesan, M.; Edelmann, M.J. Deubiquitinating enzymes as promising drug targets for infectious diseases. Curr. Pharm. Des. 2013, 19, 3234–3247. [Google Scholar] [CrossRef]
87. Wang, Y.-T.; Chen, G.-C. The role of ubiquitin system in autophagy. In Autophagy in Current Trends in Cellular Physiology and Pathology; In Tech: Rijeka, Croatia, 2016. [Google Scholar]
88. Kevei, É.; Pokrzywa, W.; Hoppe, T. Repair or destruction-an intimate liaison between ubiquitin ligases and molecular chaperones in proteostasis. FEBS Lett. 2017, 591, 2616–2635. [Google Scholar] [CrossRef] [PubMed]
89. Srinivasan, V.; Bruelle, C.; Scifo, E.; Pham, D.D.; Soliymani, R.; Lalowski, M.; Lindholm, D. Dynamic Interaction of USP14 with the Chaperone HSC70 Mediates Crosstalk between the Proteasome, ER Signaling, and Autophagy. iScience 2020, 23, 100790. [Google Scholar] [CrossRef] [PubMed]
90. He, W.T.; Zheng, X.M.; Zhang, Y.H.; Gao, Y.G.; Song, A.X.; van der Goot, F.G.; Hu, H.Y. Cytoplasmic Ubiquitin-Specific Protease 19 (USP19) Modulates Aggregation of Polyglutamine-Expanded Ataxin-3 and Huntingtin through the HSP90 Chaperone. PLoS ONE 2016, 11, e0147515. [Google Scholar] [CrossRef]
91. Lee, J.G.; Kim, W.; Gygi, S.; Ye, Y. Characterization of the deubiquitinating activity of USP19 and its role in endoplasmic reticulum-associated degradation. J. Biol. Chem. 2014, 289, 3510–3517. [Google Scholar] [CrossRef] [PubMed]
92. Gallego, D.; Leal, F.; Gámez, A.; Castro, M.; Navarrete, R.; Sanchez-Lijarcio, O.; Vitoria, I.; Bueno-Delgado, M.; Belanger-Quintana, A.; Morais, A.; et al. Pathogenic variants of DNAJC12 and evaluation of the encoded cochaperone as a genetic modifier of hyperphenylalaninemia. Hum. Mutat. 2020, 41, 1329–1338. [Google Scholar] [CrossRef] [PubMed]
93. Blau, N.; Erlandsen, H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol. Genet. Metab. 2004, 82, 101–111. [Google Scholar] [CrossRef] [PubMed]
94. Pey, A.L.; Stricher, F.; Serrano, L.; Martinez, A. Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am. J. Hum. Genet. 2007, 81, 1006–1024. [Google Scholar] [CrossRef]
95. Yang, S.; Siepka, S.M.; Cox, K.H.; Kumar, V.; de Groot, M.; Chelliah, Y.; Chen, J.; Tu, B.; Takahashi, J.S. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice. Proc. Natl. Acad. Sci. USA 2019, 116, 22229–22236. [Google Scholar] [CrossRef]
96. Shen, N.; Heintz, C.; Thiel, C.; Okun, J.G.; Hoffmann, G.F.; Blau, N. Co-expression of phenylalanine hydroxylase variants and effects of interallelic complementation on in vitro enzyme activity and genotype-phenotype correlation. Mol. Genet. Metab. 2016, 117, 328–335. [Google Scholar] [CrossRef]
97. Liang, Y.; Huang, M.Z.; Cheng, C.Y.; Chao, H.K.; Fwu, V.T.; Chiang, S.H.; Hsiao, K.J.; Niu, D.M.; Su, T.S. The mutation spectrum of the phenylalanine hydroxylase (PAH) gene and associated haplotypes reveal ethnic heterogeneity in the Taiwanese population. J. Hum. Genet. 2014, 59, 145–152. [Google Scholar] [CrossRef] [PubMed]
98. Cerreto, M.; Cavaliere, P.; Carluccio, C.; Amato, F.; Zagari, A.; Daniele, A.; Salvatore, F. Natural phenylalanine hydroxylase variants that confer a mild phenotype affect the enzyme’s conformational stability and oligomerization equilibrium. Biochim. Biophys. Acta 2011, 1812, 1435–1445. [Google Scholar] [CrossRef] [PubMed]
99. Pey, A.L.; Pérez, B.; Desviat, L.R.; Martínez, M.A.; Aguado, C.; Erlandsen, H.; Gámez, A.; Stevens, R.C.; Thórólfsson, M.; Ugarte, M.; et al. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum. Mutat. 2004, 24, 388–399. [Google Scholar] [CrossRef] [PubMed]
100. Barral, J.M.; Broadley, S.A.; Schaffar, G.; Hartl, F.U. Roles of molecular chaperones in protein misfolding diseases. Semin. Cell Dev. Biol. 2004, 15, 17–29. [Google Scholar] [CrossRef]
101. Anikster, Y.; Haack, T.B.; Vilboux, T.; Pode-Shakked, B.; Thöny, B.; Shen, N.; Guarani, V.; Meissner, T.; Mayatepek, E.; Trefz, F.K.; et al. Biallelic Mutations in DNAJC12 Cause Hyperphenylalaninemia, Dystonia, and Intellectual Disability. Am. J. Hum. Genet. 2017, 100, 257–266. [Google Scholar] [CrossRef]
102. Valenzuela, V.; Jackson, K.L.; Sardi, S.P.; Hetz, C. Gene Therapy Strategies to Restore ER Proteostasis in Disease. Mol. Ther. 2018, 26, 1404–1413. [Google Scholar] [CrossRef]
103. Ebrahimi-Fakhari, D.; Wahlster, L.; McLean, P.J. Molecular chaperones in Parkinson’s disease—Present and future. J. Parkinsons Dis. 2011, 1, 299–320. [Google Scholar] [CrossRef]
104. Aktuglu-Zeybek, A.C.; Zubarioglu, T. Nitisinone: A review. Orphan Drugs Res. Rev. 2017, 7, 25–35. [Google Scholar] [CrossRef]
105. Angileri, F.; Morrow, G.; Roy, V.; Orejuela, D.; Tanguay, R.M. Heat shock response associated with hepatocarcinogenesis in a murine model of hereditary tyrosinemia type I. Cancers 2014, 6, 998–1019. [Google Scholar] [CrossRef] [PubMed]
106. Hanpude, P.; Bhattacharya, S.; Dey, A.K.; Maiti, T.K. Deubiquitinating enzymes in cellular signaling and disease regulation. IUBMB Life 2015, 67, 544–555. [Google Scholar] [CrossRef] [PubMed]
107. Lee, B.H.; Lee, M.J.; Park, S.; Oh, D.C.; Elsasser, S.; Chen, P.C.; Gartner, C.; Dimova, N.; Hanna, J.; Gygi, S.P.; et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010, 467, 179–184. [Google Scholar] [CrossRef] [PubMed]
108. Seneci, P. Targeting Proteasomal Degradation of Soluble, Misfolded Proteins: Ubi Major. In Chemical Modulators of Protein Misfolding and Neurodegenerative Disease; Academic Press: Milan, Italy, 2015; pp. 73–94. [Google Scholar] [CrossRef]
109. Al Hafid, N.; Christodoulou, J. Phenylketonuria: A review of current and future treatments. Transl. Pediatr. 2015, 4, 304–317. [Google Scholar] [CrossRef] [PubMed]
110. Strisciuglio, P.; Concolino, D. New Strategies for the Treatment of Phenylketonuria (PKU). Metabolites 2014, 4, 1007–1017. [Google Scholar] [CrossRef]
111. Malik, S.; NiMhurchadha, S.; Jackson, C.; Eliasson, L.; Weinman, J.; Roche, S.; Walter, J. Treatment Adherence in Type 1 Hereditary Tyrosinaemia (HT1): A Mixed-Method Investigation into the Beliefs, Attitudes and Behaviour of Adolescent Patients, Their Families and Their Health-Care Team. JIMD Rep. 2015, 18, 13–22. [Google Scholar] [CrossRef] [PubMed]
112. Chinsky, J.M.; Singh, R.; Ficicioglu, C.; van Karnebeek, C.D.M.; Grompe, M.; Mitchell, G.; Waisbren, S.E.; Gucsavas-Calikoglu, M.; Wasserstein, M.P.; Coakley, K.; et al. Diagnosis and treatment of tyrosinemia type I: A US and Canadian consensus group review and recommendations. Genet. Med. 2017, 19. [Google Scholar] [CrossRef]
113. Yin, H.; Xue, W.; Chen, S.; Bogorad, R.L.; Benedetti, E.; Grompe, M.; Koteliansky, V.; Sharp, P.A.; Jacks, T.; Anderson, D.G. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 2014, 32, 551–553. [Google Scholar] [CrossRef]
114. VanLith, C.; Guthman, R.; Nicolas, C.T.; Allen, K.; Du, Z.; Joo, D.J.; Nyberg, S.L.; Lillegard, J.B.; Hickey, R.D. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1. Hum. Gene Ther. 2018, 29, 1315–1326. [Google Scholar] [CrossRef]
115. Sarkissian, C.N.; Gámez, A. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now? Mol. Genet. Metab. 2005, 86 (Suppl. 1), S22–S26. [Google Scholar] [CrossRef]
116. Thomas, J.; Levy, H.; Amato, S.; Vockley, J.; Zori, R.; Dimmock, D.; Harding, C.O.; Bilder, D.A.; Weng, H.H.; Olbertz, J.; et al. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Mol. Genet. Metab. 2018, 124, 27–38. [Google Scholar] [CrossRef]
117. Sarkissian, C.N.; Gámez, A.; Wang, L.; Charbonneau, M.; Fitzpatrick, P.; Lemontt, J.F.; Zhao, B.; Vellard, M.; Bell, S.M.; Henschell, C.; et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl. Acad. Sci. USA 2008, 105, 20894–20899. [Google Scholar] [CrossRef]
118. Alexander, I.E.; Cunningham, S.C.; Logan, G.J.; Christodoulou, J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther. 2008, 15, 831–839. [Google Scholar] [CrossRef] [PubMed]
119. Rebuffat, A.; Harding, C.O.; Ding, Z.; Thöny, B. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Hum. Gene Ther. 2010, 21, 463–477. [Google Scholar] [CrossRef] [PubMed]
120. Pan, Y.; Shen, N.; Jung-Klawitter, S.; Betzen, C.; Hoffmann, G.F.; Hoheisel, J.D.; Blau, N. CRISPR RNA-guided FokI nucleases repair a PAH variant in a phenylketonuria model. Sci. Rep. 2016, 6, 35794. [Google Scholar] [CrossRef]
121. Lachmann, R. Sapropterin hydrochloride: Enzyme enhancement therapy for phenylketonuria. Ther. Adv. Endocrinol. Metab. 2011, 2, 127–133. [Google Scholar] [CrossRef] [PubMed]
122. Charbonneau, M.R.; Isabella, V.M.; Li, N.; Kurtz, C.B. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat. Commun. 2020, 11, 1–11. [Google Scholar]
123. Alteri, C.J. Can the Microbiome Deliver? A Proof-of-Concept Engineered E. coli PKU Therapeutic. Cell Host Microbe 2019, 25, 473–474. [Google Scholar] [CrossRef]
124. Kochhar, J.S.; Chan, S.Y.; Ong, P.S.; Kang, L. Clinical therapeutics for phenylketonuria. Drug Deliv. Transl. Res. 2012, 2, 223–237. [Google Scholar] [CrossRef]
125. Patrawala, M.; Kuruvilla, M.; Li, H. Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria. Mol. Genet. Metab. Rep. 2020, 23, 100575. [Google Scholar] [CrossRef]
126. Markham, A. Pegvaliase: First Global Approval. BioDrugs 2018, 32, 391–395. [Google Scholar] [CrossRef]
127. Longo, N.; Arnold, G.L.; Pridjian, G.; Enns, G.M.; Ficicioglu, C.; Parker, S.; Cohen-Pfeffer, J.L. Long-term safety and efficacy of sapropterin: The PKUDOS registry experience. Mol. Genet. Metab. 2015, 114, 557–563. [Google Scholar] [CrossRef]
128. Rohr, F.; Kritzer, A.; Harding, C.O.; Viau, K.; Levy, H.L. Discontinuation of Pegvaliase therapy during maternal PKU pregnancy and postnatal breastfeeding: A case report. Mol. Genet. Metab. Rep. 2020, 22, 100555. [Google Scholar] [CrossRef] [PubMed]
129. Das, A.M. Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1). Appl. Clin. Genet. 2017, 10, 43–48. [Google Scholar] [CrossRef]
130. Muntau, A.C.; Leandro, J.; Staudigl, M.; Mayer, F.; Gersting, S.W. Innovative strategies to treat protein misfolding in inborn errors of metabolism: Pharmacological chaperones and proteostasis regulators. J. Inherit. Metab. Dis. 2014, 37, 505–523. [Google Scholar] [CrossRef] [PubMed]
131. Lichter-Konecki, U.; Vockley, J. Phenylketonuria: Current Treatments and Future Developments. Drugs 2019, 79, 495–500. [Google Scholar] [CrossRef]
132. Ernst, R.; Claessen, J.H.; Mueller, B.; Sanyal, S.; Spooner, E.; van der Veen, A.G.; Kirak, O.; Schlieker, C.D.; Weihofen, W.A.; Ploegh, H.L. Enzymatic blockade of the ubiquitin-proteasome pathway. PLoS Biol. 2011, 8, e1000605. [Google Scholar] [CrossRef]
133. Wang, Y.; Jiang, X.; Feng, F.; Liu, W.; Sun, H. Degradation of proteins by PROTACs and other strategies. Acta Pharm. Sin. B 2020, 10, 207–238. [Google Scholar] [CrossRef]
134. Smith, B.E.; Wang, S.L.; Jaime-Figueroa, S.; Harbin, A.; Wang, J.; Hamman, B.D.; Crews, C.M. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat. Commun. 2019, 10, 131. [Google Scholar] [CrossRef] [PubMed]
135. Nguyen, T.; Ho, M.; Kim, K.; Yun, S.I.; Mizar, P.; Easton, J.W.; Lee, S.S.; Kim, K.K. Suppression of the Ubiquitin Pathway by Small Molecule Binding to Ubiquitin Enhances Doxorubicin Sensitivity of the Cancer Cells. Molecules 2019, 24, 1073. [Google Scholar] [CrossRef] [PubMed]
136. Landré, V.; Rotblat, B.; Melino, S.; Bernassola, F.; Melino, G. Screening for E3-ubiquitin ligase inhibitors: Challenges and opportunities. Oncotarget 2014, 5, 7988–8013. [Google Scholar] [CrossRef]